New research advances and future prospect in precision treatment of triple-negative breast cancer
According to the latest data released by the Cancer Research Institute of the World Health Organization, breast cancer has replaced lung cancer as the malignant tumor with the highest incidence rate in the world. Triple-negative breast cancer (TNBC) is defined by a lack of estrogen receptor (ER), pr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2022-08-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1663559391064-707647498.pdf |
| _version_ | 1818020065453277184 |
|---|---|
| author | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin |
| author_facet | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin |
| author_sort | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin |
| collection | DOAJ |
| description | According to the latest data released by the Cancer Research Institute of the World Health Organization, breast cancer has replaced lung cancer as the malignant tumor with the highest incidence rate in the world. Triple-negative breast cancer (TNBC) is defined by a lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other types of breast cancer, TNBC bears the characteristics of high metastasis rate, strong invasiveness and poor prognosis. TNBC is not sensitive to endocrine therapy and anti-HER2 therapy, and chemotherapy is its main systemic treatment. With the vigorous development of genomics, transcriptomics, metabolomics, proteomics, microbiomics technologies and the in-depth study of TNBC molecular subtyping, targeted therapy and immunotherapy drugs, including poly(ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2) antibody-drug conjugate, pembrolizumab, atezolizumab, durvalumab, etc., have provided new therapeutic methods, which are changing the clinical practice and treatment pattern of TNBC. It is believed accurate therapy will become a new direction of development in the future. Based on the molecular subtypes of TNBC, here we summarized the research advances in targeted therapy and immunotherapy of TNBC, in order to provide reference for the precise treatment strategy of TNBC in the future. |
| first_indexed | 2024-04-14T08:00:04Z |
| format | Article |
| id | doaj.art-26befc87444043bf8abda6f98d8f029c |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-04-14T08:00:04Z |
| publishDate | 2022-08-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-26befc87444043bf8abda6f98d8f029c2022-12-22T02:04:55ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392022-08-0132866967910.19401/j.cnki.1007-3639.2022.08.001New research advances and future prospect in precision treatment of triple-negative breast cancerXIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin0Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaAccording to the latest data released by the Cancer Research Institute of the World Health Organization, breast cancer has replaced lung cancer as the malignant tumor with the highest incidence rate in the world. Triple-negative breast cancer (TNBC) is defined by a lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other types of breast cancer, TNBC bears the characteristics of high metastasis rate, strong invasiveness and poor prognosis. TNBC is not sensitive to endocrine therapy and anti-HER2 therapy, and chemotherapy is its main systemic treatment. With the vigorous development of genomics, transcriptomics, metabolomics, proteomics, microbiomics technologies and the in-depth study of TNBC molecular subtyping, targeted therapy and immunotherapy drugs, including poly(ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2) antibody-drug conjugate, pembrolizumab, atezolizumab, durvalumab, etc., have provided new therapeutic methods, which are changing the clinical practice and treatment pattern of TNBC. It is believed accurate therapy will become a new direction of development in the future. Based on the molecular subtypes of TNBC, here we summarized the research advances in targeted therapy and immunotherapy of TNBC, in order to provide reference for the precise treatment strategy of TNBC in the future.http://www.china-oncology.com/fileup/1007-3639/PDF/1663559391064-707647498.pdf|triple-negative breast cancer|molecular subtypes|precision therapy|targeted therapy|immunotherapy |
| spellingShingle | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin New research advances and future prospect in precision treatment of triple-negative breast cancer Zhongguo aizheng zazhi |triple-negative breast cancer|molecular subtypes|precision therapy|targeted therapy|immunotherapy |
| title | New research advances and future prospect in precision treatment of triple-negative breast cancer |
| title_full | New research advances and future prospect in precision treatment of triple-negative breast cancer |
| title_fullStr | New research advances and future prospect in precision treatment of triple-negative breast cancer |
| title_full_unstemmed | New research advances and future prospect in precision treatment of triple-negative breast cancer |
| title_short | New research advances and future prospect in precision treatment of triple-negative breast cancer |
| title_sort | new research advances and future prospect in precision treatment of triple negative breast cancer |
| topic | |triple-negative breast cancer|molecular subtypes|precision therapy|targeted therapy|immunotherapy |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1663559391064-707647498.pdf |
| work_keys_str_mv | AT xiaoyulingzhuxiuzhijiangyizhoushaozhimin newresearchadvancesandfutureprospectinprecisiontreatmentoftriplenegativebreastcancer |